Last mentioned: Feb 19, 2026
As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
The rapid adoption of GLP-1 receptor agonists is catalyzing a shift toward 'companion nutrition' to address muscle loss and nutrient deficiencies. This evolution is driving a multi-billion dollar secondary market for specialized food products and integrated digital health monitoring tools.
Rising temperatures and shifting weather patterns are projected to reduce suitable coffee-growing land by up to 50% by 2050. Without immediate investment in farm-level adaptation and resilient crop varieties, the retail sector faces permanent price hikes and chronic supply shortages.